A “living drug” that could change the way we treat cancer | Carl June

Episode Summary

Executive Summary: Immunologist Carl June explains how CAR T-cell therapy transformed cancer treatment by engineering a patient’s own immune cells into a synthetic, living drug. Through years of setbacks, key clinical breakthroughs, and a dramatic rescue of a dying child, he shows how CAR T can produce durable remissions in otherwise incurable leukemia and lymphoma, while also raising questions about toxicity, cost, and access.

Main Topics: Why the immune system struggles against cancer (Priority: 5/5): June explains that the immune system evolved to fight external pathogens, not cancers arising from the body’s own cells, which makes most tumors hard to detect without causing autoimmunity. Engineering synthetic immune systems (Priority: 5/5): The talk introduces CAR T cells as a synthetic immune system built by inserting antibody genes into T cells using genetic engineering and synthetic biology, repurposing B-cell and T-cell functions to target cancer. CAR T as a living drug (Priority: 5/5): Unlike conventional drugs, CAR T cells expand inside the body, persist for years, and can continue patrolling long after infusion, making them a fundamentally new therapeutic paradigm. Clinical breakthroughs in leukemia (Priority: 5/5): June recounts early patient cases, including adults with advanced CLL and children with acute leukemia, where CAR T produced dramatic tumor clearance and durable remissions. Cytokine release syndrome and tocilizumab (Priority: 4/5): The severe inflammatory reaction seen in responders, especially Emily Whitehead, led to the identification of cytokine release syndrome and the use of tocilizumab to control IL-6-driven toxicity. Regulatory approval and broader impact (Priority: 4/5): The talk highlights FDA approvals for pediatric/young adult leukemia and refractory lymphoma, marking CAR T as the first approved cell and gene therapy and signaling broader clinical potential. Cost, access, and the long road of discovery (Priority: 4/5): June closes by noting the high cost of manufacturing and treating complications, while emphasizing that the therapy emerged from a 30-year journey of persistence and scientific iteration.

Key Arguments: Cancer is difficult for the immune system to attack because it originates from the body’s own cells, so natural immune responses often fail or cause autoimmune harm. CAR T cells solve this by combining B-cell antibody specificity with T-cell killing power through genetic engineering. Using an HIV-based vector as a delivery tool enabled insertion of the CAR construct into T cells. CAR T cells can proliferate massively in patients and eliminate large tumor burdens, functioning as a living drug rather than a temporary chemical treatment. Durable remissions in advanced leukemia patients suggest that some may be cured, not merely treated. Severe cytokine release syndrome is a sign of strong immune activation and can be managed with tocilizumab, which improved safety and enabled broader use. The therapy’s success in children and adults led to FDA approvals, validating cell and gene therapy as a new medical category. High manufacturing and treatment costs are a major barrier, but the cost of failure in terminal cancer is even greater. Scientific breakthroughs often require decades of persistence, setbacks, and unexpected turns rather than immediate success.

Data Points: CAR T persistence in patients: more than 8 years - June says CAR T cells have remained in some cancer patients’ bodies for over eight years. Calculated CAR T half-life: more than 17 years - He describes designer CAR T cells as having a long calculated half-life, implying long-term persistence. Initial leukemia patients treated: 3 patients - In 2012, his team treated three patients with advanced chronic lymphocytic leukemia. Durable remissions in first cohort: 2 of 3 patients - Two of the first three CLL patients achieved durable remissions lasting eight years. Tumor mass dissolved per patient: 2.9 to 7.7 pounds - He reports the amount of tumor eliminated in the early leukemia cases. CAR T killing ratio: 1 to 1,000 - One CAR T cell can kill about 1,000 tumor cells. Emily Whitehead age at treatment: 6 years old - She was the first pediatric patient described in the talk. Emily’s fever peak: 106°F for 3 days - During cytokine release syndrome, she developed extreme fevers while in ICU. IL-6 elevation: more than 1,000-fold above normal - Her blood showed extreme interleukin-6 levels, prompting use of tocilizumab. Response to tocilizumab: within hours - Emily began improving rapidly after receiving the IL-6-blocking drug. Emily remission timing: 23 days - She was declared cancer-free 23 days after CAR T treatment. Early trial remission rate: 27 of 30 patients (90%) - June cites the first 30 patients treated, with 27 complete remissions within a month. FDA approval year for pediatric/young adult leukemia: August 2017 - He notes this as the first approval of a cell and gene therapy. Approximate annual U.S. incidence of CLL: 20,000 adults per year - He describes chronic lymphocytic leukemia as affecting about 20,000 adults annually in the U.S. Approximate annual U.S. incidence of refractory lymphoma: 20,000 per year - He gives a similar annual figure for advanced lymphoma. Manufacturing cost per patient: up to $150,000 - He estimates the cost to make CAR T cells for one patient. Total cost with complications: up to $1 million per patient - Including CRS and other complications, treatment can become extremely expensive.

Pivotal Quotes: "if you come to a fork in the road, take it." — Carl June: He opens with Yogi Berra’s line to frame the unexpected turns that led to CAR T therapy. "CAR T cells are the first living drug in medicine." — Carl June: He explains why CAR T differs fundamentally from conventional drugs. "Sometimes, even though we may not know it at the time, the fork is the way home." — Carl June: His closing reflection on persistence, setbacks, and scientific discovery.

Implications: CAR T therapy shows that engineered immune cells can produce durable cancer remissions and reshape oncology, but broader impact depends on safer toxicity management, lower costs, and wider access. It also signals a future where cell and gene therapies become mainstream.